The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A comparison of induction and maintenance therapy for acute nonlymphocytic leukemia in childhood: results of a Pediatric Oncology Group study.
C P Steuber; C Civin; J Krischer; S Culbert; A Ragab; F B Ruymann; Y Ravindranath; B Leventhal; R Wilkinson; T J Vietti (Profiled Author: Curt I Civin)
Baylor College of Medicine, Houston, TX.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(2):247-58.
Two hundred fifty-six children with previously untreated acute nonlymphocytic leukemia (ANLL) were evaluated on a Pediatric Oncology Group (POG) phase III randomized trial of both induction and continuation chemotherapies. Induction therapy compared vincristine, cytarabine, and dexamethasone (VADx) with daunorubicin, cytarabine, and thioguanine (DAT). The complete remission (CR) rate using DAT was superior (82% v 61%, P = .02). Postremission therapy consisted of either "standard" two-cycle therapy or a more intensive four-cycle regimen given for 2 years. Overall, there was no difference in outcome for patients randomized to either continuation regimen. The overall complete continuous remission rate (CCR) for the "best" induction/continuation therapy combination at 2 years was .50 (SE = .06), at 3 years was .35 (.04), and at 4 years was .34 (.05). Analysis of selected clinical and laboratory parameters demonstrated differences in induction responses favoring DAT induction but did not impact eventual disease-free survival. There were two subgroups of patients who responded better to four-cycle continuation therapy. These were patients with French-American-British (FAB) M1/M2 (2-year CCR was .20 v .44, P = .01) and patients older than 10 years at diagnosis (.32 v .62, P = .004).
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
D M Loeb; D C Bowers; C I Civin; A D FriedmanMedical and pediatric oncology 2001;37(4):365-71.
H Weinstein; Y Ravindranath; J Krischer; P Steuber; C Civin; M Gresik; T ViettiLeukemia 1992;6 Suppl 2():52-4.
Maria R Baer; Stephen L George; Richard K Dodge; Kieran L O'Loughlin; Hans Minderman; Michael A Caligiuri; John Anastasi; Bayard L Powell; Jonathan E Kolitz; Charles A Schiffer; et al.Blood 2002;100(4):1224-32.
Appears in this Publication
Author of this Publication